Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AAF Altachem Pharma -- Ignore unavailable to you. Want to Upgrade?

To: ciderapple who wrote (20)	6/7/1999 10:52:00 AM
From: terry	Respond to of 42

Roger, don't know if you saw this. Released last Wed. "June 2, 1999 02:36 PM LAS VEGAS--(BW HealthWire)--June 2, 1999--Steroidogenesis Inhibitors International STGI today reported that the Romanian Institute of Oncology and the Pasteur Institute in Bucharest indicated favorable preliminary results on aging and cancer treatment from Steroidogenesis' ANTICORT(tm). Dr. Nicolae Voiculetz, the lead scientist, interviewed in Bucharest's The Financial Journal, and other Romanian newspapers, reported that by using the drug ANTICORT(tm) on fibroblast cells grown on tissue cultures, there was an extension of their life by 75%. Dr. Voiculetz said that these results, while preliminary, brought important information not only about the aging process, but in the field of cancer treatment. ANTICORT is STGI's flagship anticortisol drug developed to treat "high cortisol" diseases. It has been demonstrated that cortisol, a powerful immunosuppressive hormone, is the cause of diseases/symptoms of diseases, which can be treated successfully with anticortisol drugs. Diseases associated with "high" cortisol include depression, anorexia nervosa, high blood pressure (hypertension), gastrointestinal ulcers, myocardial infarction, diabetes, rheumatoid arthritis, infectious diseases (AIDS, viral hepatitis, recurrent herpes genitalis), multiple sclerosis (MS), Parkinson's, aging/Alzheimer's and cancers of breast, uterine and prostate."

To: ciderapple who wrote (20)	6/15/1999 10:54:00 AM
From: terry	Read Replies (1) \| Respond to of 42

NEWS!!! Altachem Pharma completes technology transfer for HCG molecule Altachem Pharma Ltd AAF Shares issued 14,735,899 1999-06-08 close $0.5 Tuesday Jun 15 1999 Mr. Warren Jackson reports Altachem Pharma Ltd. has completed the technology transfer (entire rights to the patent rights to make, have made, use, lease, sell, import and export technology products and to practice the technology process) in the territory (shall mean the world) with the University of Montreal and Dr. Tony Antakly, for the HCG molecule and the option for two retenoids. Dr. Tony Antakly, professor of biochemistry at the University of Montreal and director of the molecular biopathology laboratory discovered a novel protein with potent anti-HIV and Kaposi's sarcoma activity, which he extracted from pregnancy urine. Laboratory studies indicate that molecules associated with the pregnancy hormone HCG may be effective against AIDS and its associated cancer Kaposi's sarcoma. Thus, this discovery provides a solid basis for development of a novel Kaposi sarcoma and AIDS therapy. The molecule is dubbed as HIP (HCG-like and HIV inhibitory protein). Laboratory experiments have shown that HCG preparations display significant inhibitory action on KS cell growth as well as demonstrating its anti-HIV activity. Furthermore, HIP treatment of human lymphocytes infected with the HIV virus resulted in a significant inhibition of HIV expression. A world patent has been submitted for the HIP molecule. At the moment, the HIP molecule is in preclinical status. The current HAART (highly active antiretroviral therapy) commonly used for HIV treatment, though effective, display nonetheless severe side effects. Furthermore, resistance to the drugs is now emerging after over two years of widespread use. The prolonged administration of these HAART therapies in some cases necessitate discontinuation. Alternative therapies are urgently required. Natural substances, including hormones, antihormones and its analogues, are increasingly being used as milder therapeutic agents which target specific receptor-expressing cells. Anticort status Since obtaining the health protection branch "no objection" letter to proceed with clinical trials, the proposed clinical study has been submitted to the institutional ethics board for its approval to start the clinical trials. If the safety and efficiency of these three natural molecules (HIP and the two retenoids) and Anticort can be positively demonstrated in the human clinical trials, then Altachem Pharma will proceed to develop and formulate its own AIDS drugs. These are expected to provide a milder therapeutic treatment, with fewer side effects than the current HAART therapies. Altachem Pharma Ltd. is participating, via a trade booth and presentation, in a technology investment forum in Edmonton, Alta., on June 22, 1999, at the Delta Edmonton South Hotel and Conference Centre and in Calgary, Alta., on June 24, 1999, at the Calgary Convention Centre. These single-day events offer you the opportunity to meet directly with the management team of Altachem Pharma Ltd. to learn first-hand from newsletter editor panels and financial analysts about investment opportunities. Please come and visit the company's booth. For more information on attending the Cambridge House international forum, call 1-877-363-3356. WARNING: The company relies on litigation protection for "forward-looking" statements. (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com